Filtricine, Inc.

Filtricine, Inc. is a health-focused company developing Tality, a nutritional product aimed at supporting cancer patients during treatment. The company is dedicated to advancing dietary solutions tailored for oncology care. Filtricine, Inc.

was founded in 2017 in Sunnyvale, US, and specializes in clinical nutrition for cancer patients. The company is co-founded by Grace Yang and Xin Wang, with John Chant serving as CEO. Filtricine has completed four deals since its inception, with the most recent deal occurring on August 29, 2022, which involved raising seed funding from returning investor SOSV. Filtricine, Inc.

specializes in developing Tality, a revolutionary food product currently undergoing clinical investigation for cancer treatment. Tality is designed as a proprietary nutritional regimen of meal replacements that deprives cancer cells of non-essential amino acids while preserving essential nutrients. This innovative approach is being tested in clinical trials, particularly for prostate cancer patients at Stanford University School of Medicine, and is available at no cost to participating cancer patients. Filtricine primarily targets the North American market, focusing on regions with comprehensive cancer care facilities.

Filtricine generates revenue through its clinical trial programs and partnerships with healthcare providers involved in cancer care. Its flagship product, Tality, is distributed through clinical trials, allowing patients to access it at no cost while contributing to research. Revenue is structured around agreements with medical centers to supply Tality for clinical assessments, aiding future commercialization strategies as the company advances through trial phases. Filtricine, Inc.

plans to utilize the funding raised in August 2022 to support the ongoing clinical trials of Tality and explore new product developments. The company is focusing on expanding its reach within the North American market, particularly aiming to establish partnerships with additional oncology specialists and healthcare systems. As Tality progresses through its clinical trial phases, Filtricine anticipates potential revenue growth through expanded distribution channels and strategic collaborations.